|
|
|
|
|
Wen-Chin Ko, Chia-Ti Tsai, Kai-Cheng Hsu, Yu-Che Cheng, Tony Eight Lin, Yi-Ling Chen, Chuang-Ye Hong, Wan-Jung Lu, Chun-Ming Shih and Ting-Lin Yen
Treatment of magnolol represents a new therapeutic strategy that may reduce the risk of vascular diseases associated with abnormal vascular smooth muscle cell (VSMC) migration or thrombin/protease-activated receptor 1 (PAR-1) activation.
|
|
|
|
|